Picture

Northwestern Medicine
​Breakthroughs for Physicians

​​
  • Home
  • Specialties
    • Cardiovascular >
      • Research
      • Clinical Breakthroughs
      • News
    • Endocrinology >
      • Clinical Breakthroughs In Endocrinology
      • Research In Endocrinology
      • News
    • ENT (Otolaryngology) >
      • Clinical Breakthroughs
      • Research
      • News
    • Gastroenterology >
      • Clinical Breakthroughs
      • Research
      • News
    • Geriatrics >
      • Clinical Breakthroughs
      • Research
      • News
    • Neurosciences >
      • Rare and Complex Brain Tumors
      • Research
      • COVID-19 and Neurosciences
      • News
      • Clinical Breakthroughs
    • OB-GYN >
      • Clinical Breakthroughs
      • Research
      • News
    • Oncology >
      • Clinical Breakthroughs
      • Research
      • News
    • Ophthalmology >
      • Clinical Breakthroughs
      • Research
      • News
    • Organ Transplant >
      • Clinical Breakthroughs
      • Research
      • News
    • Orthopaedics >
      • Clinical Breakthroughs
      • Research
      • News
    • Psychiatry >
      • Clinical Breakthroughs
      • Research
      • News
    • Pulmonary >
      • Clinical Breakthroughs
      • Research
      • News
    • Rehabilitation >
      • Clinical Breakthroughs
      • News
    • Rheumatology >
      • Clinical Breakthroughs
      • Research
      • News
    • Urology >
      • Clinical Breakthroughs
      • Research
      • News
  • CME
  • REFERRALS
    • Refer to NM Cardiovascular
    • Refer to NM Neurosciences
    • Refer to Other Specialties

< BACK TO RESEARCH IN ONCOLOGY

< BACK TO RESEARCH IN UROLOGY

March 2023

ONCOLOGY

HORMONE THERAPY PLUS CURRENT TREATMENTS IMPROVES SURVIVAL IN PROSTATE CANCER

Featuring: ​Maha Hussain, MD, FACP, FASCO ​

​Combining a new hormone therapy drug with chemotherapy and another hormone therapy increased overall survival in patients with high-volume and both high-risk and low-risk metastatic hormone-sensitive prostate cancer (mHSPC), according to a post hoc analysis published in the Journal of Clinical Oncology.

Maha Hussain, MD, FACP, FASCO, the Genevieve E. Teuton Professor of Medicine in the Division of Hematology and Oncology and deputy director of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, was lead author of the study, a secondary analysis of the results of a large, multi-site international clinical trial.

In patients with mHSPC, prostate cancer can be successfully treated with hormone therapy. Because mHSPC is driven by the male sex hormone androgen, the cancer is treated with androgen-deprivation therapy (ADT) to help block or stop cancer growth.

While most mHSPC patients have elevated hormone levels in the testicular region, about five percent are extragonadal, providing an opportunity to combine ADT with other targeted therapies like androgen receptor/pathway inhibitors (AR-Is).

​In a previous randomized, phase III clinical trial called the ARASENS trial, of which Hussain was also a co-author, investigators evaluated the efficacy and safety of two therapeutic approaches in mHSPC patients: darolutamide (an AR-I) plus docetaxel (a chemotherapy drug) plus ADT versus placebo plus docetaxel plus ADT. 

In the ARASENS trial, patients who received the darolutamide combination therapy approach demonstrated an increase in overall survival.

In the current study, a secondary analysis of the ARASENS trial, the investigators evaluated the efficacy and safety of the aforementioned therapeutic approaches in mHSPC patient subgroups determined by disease volume and risk. Of the 1,300 study participants, 77 percent had high-volume disease and 70 percent had high-risk disease, respectively.

​The investigators then compared the following outcomes in both groups: overall survival, progression to castration resistance and other outcomes compared to placebo based on disease volume and disease risk.

At the end of the study period, darolutamide increased overall survival compared to placebo in the overall patient population and patients with high-volume, high-risk mHSPC as well as in patients with low-risk mHSPC. Trends in low-volume mHSPC also favored the triplet therapy. The darolutamide group also demonstrated improvements in time to castration-resistant prostate cancer and subsequent systemic antineoplastic therapy.

Overall, the hazard ratio across disease volume and disease risk strongly favored the darolutamide triplet therapy, according to Hussain.

“Several potential questions now need to be evaluated and addressed, including the role of therapy holiday in long-term responders, if docetaxel chemotherapy is needed in the era of powerful AR-Is, implications of new imaging in identifying early micrometastases and how best to implement current life-prolonging therapies, amongst other questions,” Hussain said.

This work was supported by Bayer AG and Orion Pharma.
 
This article was originally published in the Feinberg School of Medicine News Center on March 22, 2023. ​
Maha Hussain, MD, FACP, FASCO headshot
Maha Hussain, MD, FACP, FASCO the Genevieve E. Teuton Professor of Medicine in the Division of Hematology and Oncology and deputy director of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, was lead author of the study published in the Journal of Clinical Oncology.

Refer a Patient

Northwestern Medicine welcomes the opportunity to partner with you in caring for your patients. ​
Call 844.344.6663
Find an NM PULMONOLOGIST

You May Also Like

Bin Zhang, MD, PHD Headshot

December 2022

ONCOLOGY
Bin Zhang, MD, PHD, Named Co-leader Of Tumor Environment And Metastasis Program
Mazhar Adli, PhD headshot

February 2023

UROLOGY
Treatment Protocol for Incidental Prostate Cancer After HoLEP
Huiping Liu, MD, PhD,  headshot

October 2022

ONCOLOGY
Newly Identified Protein Drives Breast Cancer Stemness And Metastasis

Northwestern Medicine Breakthroughs for Physicians

About Us     Terms of Use     Privacy Policy     How to Vote for U.S. News & World Report Best Hospitals
© 2025 Northwestern Medicine® and Northwestern Memorial HealthCare. 
Northwestern Medicine® is a trademark of Northwestern Memorial HealthCare, used by Northwestern University
Connect with us
[email protected]
International physicians, contact [email protected]
  • Home
  • Specialties
    • Cardiovascular >
      • Research
      • Clinical Breakthroughs
      • News
    • Endocrinology >
      • Clinical Breakthroughs In Endocrinology
      • Research In Endocrinology
      • News
    • ENT (Otolaryngology) >
      • Clinical Breakthroughs
      • Research
      • News
    • Gastroenterology >
      • Clinical Breakthroughs
      • Research
      • News
    • Geriatrics >
      • Clinical Breakthroughs
      • Research
      • News
    • Neurosciences >
      • Rare and Complex Brain Tumors
      • Research
      • COVID-19 and Neurosciences
      • News
      • Clinical Breakthroughs
    • OB-GYN >
      • Clinical Breakthroughs
      • Research
      • News
    • Oncology >
      • Clinical Breakthroughs
      • Research
      • News
    • Ophthalmology >
      • Clinical Breakthroughs
      • Research
      • News
    • Organ Transplant >
      • Clinical Breakthroughs
      • Research
      • News
    • Orthopaedics >
      • Clinical Breakthroughs
      • Research
      • News
    • Psychiatry >
      • Clinical Breakthroughs
      • Research
      • News
    • Pulmonary >
      • Clinical Breakthroughs
      • Research
      • News
    • Rehabilitation >
      • Clinical Breakthroughs
      • News
    • Rheumatology >
      • Clinical Breakthroughs
      • Research
      • News
    • Urology >
      • Clinical Breakthroughs
      • Research
      • News
  • CME
  • REFERRALS
    • Refer to NM Cardiovascular
    • Refer to NM Neurosciences
    • Refer to Other Specialties